The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease

Edith Pérez de Arce, Rodrigo Quera, Eamonn M.M. Quigley

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)689-711
Number of pages23
JournalGastroenterology Clinics of North America
Issue number3
StatePublished - Sep 2021

Bibliographical note

Funding Information:
Conflicts of Interest: Drs E. Pérez de Arce and R. Quera report no conflicts. Dr E.M.M. Quigley serves as a consultant to 4D Pharma, Allergan, Atlantia, Biocodex, Ironwood, Novozymes, Precisionbiotics, Salix, and Vibrant and receives research funding from 4D Pharma , Biomerica , Vibrant , and Zealand Pharma .


  • Brain–gut axis
  • Crohn's disease
  • Fecal calprotectin
  • Inflammatory bowel disease
  • Irritable bowel syndrome
  • Microbiome
  • Ulcerative colitis

Cite this